The purpose of this paper was to (1) comprehensively analyze transplant-related costs for predicted temporal cost shifting and (2) to evaluate whether previous findings of decreasing costs of care persisted using a cost analysis of 353 NHL patients who received autologous stem cell transplantation (SCT) at the University of Nebraska Medical Center. All transplant-related costs between the patient's initial consult and program dismissal were obtained and inflated to constant 1995 dollars. Homogeneous resources were categorized into six cost-drivers and subdivided into outpatient, transplant, and additional inpatient time periods in order to evaluate resource utilization and cost shifting patterns. Between 1989 and 1991 both the average length of stay and comprehensive costs decreased 4.9 days and 14%, respectively. By 1995 additional decreases of 25.7 days and 51% led to an overall 7 year cost decline of 65%. Percent contributions of the six cost-drivers remained similar demonstrating uniformed suppression in transplant-related resource consumption. In contrast, the timing of resource utilization changed dramatically, with transplant hospitalization costs accounting for 83% of the overall costs in 1989, 71% by 1992, and only 45% in 1995, while total outpatient's contribution was 14%, 26% and 49%. Before 1991 ebbing costs were likely related to the development of new technologies such as hematopoietic growth factors and peripheral SCT, while the three-fold larger improvement in costs reported by 1995 are presumably associated with learning curve effects such as organizational changes, increased use of coordinated outpatient facilities, and the more cost-effective use of laboratory tests and pharmaceuticals.
NHL. [1] [2] [3] [4] [5] [6] [7] The diffusion of this technology in Europe and the United States is unprecedented, with over 800 cases reported to the North American Autologous Blood and Marrow Transplant Registry between 1989 and 1995, accounting for over 25% of the transplant cases recorded in their data base. 8 Despite the rapid diffusion of this technology, there is comparatively little reported information on the comprehensive costs of SCT. 9 Our earlier report from the University of Nebraska Medical Center (UNMC) indicated that costs of care for NHL patients decreased by 25% between 1987 and 1991, while the average inpatient stay decreased from 45 days to 38 days. 10 During this evaluation period, the use of hematopoietic colony-stimulating factors was a major reason for shortened periods of neutropenia, earlier discharge, and significant cost savings. More recent data on temporal changes in costs have not been reported, despite continued technological improvements and organizational changes (such as coordinated outpatient centers) for persons undergoing autologous SCT. The current study was undertaken to determine whether improvements in economic outcomes found during the first 5 years of the transplant program at UNMC persisted as the procedure continued to evolve and technological advances became more established. In addition, the possibility of cost shifting was of interest given the increased use of outpatient transplantation since 1991. As technological advances and organization changes facilitated earlier discharges and outpatient transplantation, an increase in readmission rates and outpatient costs were predicted as resource consumption shifted from the transplant admission. To investigate these questions we designed a comprehensive cost analysis which included not only the transplant hospitalization costs, but also outpatient and inpatient costs derived from the patient's pretransplant work-up and post-transplant recovery periods.
Materials and methods
A total of 427 adult patients underwent high-dose chemotherapy followed by autologous bone marrow and/or peripheral SCT for NHL at UNMC between 1 January 1989 and 31 December 1995; 353 were included in this cost analysis. The information for this study was obtained from two sources: (1) clinical data maintained by the institutional Cancer Clinical Trials Office; and (2) patient billing rec-ords. The financial department's database contains information on charges, and is categorized using cost center accounting methods. Economic data from 74 patients treated between 1989 and 1991 were not included in these analyses due to an electronic record retrieval dysfunction and the inaccessibility of microfilmed information. However, the overall costs per case, sociodemographic characteristics, and clinical outcomes, and average length of stay for these missing patients were similar to those for patients with the same diagnosis who were treated in the same year.
The economic data reported here are based on direct patient costs, not charges, as medical resource costs are more representative of true societal costs. These costs are estimated from charges using annually calculated and institutional cost center-specific ratios of costs to charges. Six cost-drivers were used to bundle numerous, but related, cost centers into resource groups which included: room, laboratory, radiology, pharmacy, supportive care and professional fees. Health care resources grouped into the room costdriver category included inpatient hospital room costs in which nursing fees were included, outpatient clinic visits, medical materials, and room-related overheads. Laboratory costs included chemistry profiles, blood work, blood bank, pulmonary function testing, heart station monitoring, and other related costs. Radiographic costs included plain films, CT scans, MRI scans, and other radiology services. Incorporated in pharmacy costs were all drugs administered as an inpatient or outpatient. Professional fees included oncology and consulting physician reimbursement. Professional fees for all patients transplanted in 1994 and 1995 were collected and an application rate was developed to estimate all professional fees. A single inflationary adjusted outpatient and additional inpatient professional fee was applied to the entire outpatient experience and each additional hospitalization, respectively. To reflect variable lengths of the transplant hospitalization, a daily application rate was used to estimate the transplantation professional fees.
The timing of resource consumption was considered in addition to assembling costs into six resource-related costdriver categories. Comprehensive costs of the total experience were separated into three cost accrual periods -outpatient, transplant hospitalization and additional inpatient periods. Outpatient costs included those incurred in the outpatient setting between the time of the patient's initial consultation and their return home following program dismissal, including the costs of the stem cell harvest (when performed as an outpatient), pretransplant and post-transplant radiographic and laboratory evaluations, and outpatient clinic visits. Included in the transplant period were high-dose therapy, transplantation (unless stem cells reinfused as an outpatient), and hematopoietic recovery-related costs. Additional inpatient costs associated with pretransplant hospitalizations for bone marrow harvesting or posttransplant admissions for regimen-related toxicities or severe neutropenic complications were delineated from the transplant hospitalization. Therefore, not only were there three major time periods in which costs were generated, but six time-sensitive cost-drivers associated with these period costs.
Historical costs were reported based on adjusted constant 1995 dollars using the Hospital and Related Services subcategorical market basket derived from the generalized Medical Care All Urban Consumer Price Index (CPI).
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Annual Hospital and Related Services CPIs were used to inflate all costs and assigned to each cost-driver individually based on the grouped economic resources it represented and the actual period of resource consumption. Future health effects were not discounted because of the short observation period.
Costs were not presented in terms of absolute dollars for several reasons. First, because of regional variations in labor costs, rent, and other non-medical costs, the absolute costs of care in Nebraska almost certainly differ from that in other geographic regions, therefore limiting the generalizability of these numbers. Second, the percent change in medical costs on an annual basis is more likely to be generalizable to other geographic regions. Improvements in technology and efficiency are likely to lead to relatively similar proportional savings in resource utilization and costs among various geographic regions in the United States. Third, competitive institutional transplantation contracting with third party payers renders the precise cost data as proprietary information to the University of Nebraska which, if disclosed publicly, might adversely affect insurance contracts for providers at the University as well as elsewhere in the United States. For these reasons costs have been standardized to have a value between 0.0 and 1.0, with 1989 costs being the baseline year and designated as a cost of 1.0.
Patients were treated with IRB-approved regimens at the time of their enrollment based on histology and chemotherapy sensitivity. Some of the high-dose chemotherapy regimens used included total body irradiation (TBI). Most patients received cyclophosphamide and TBI (Cy/TBI = 118) or BCNU, etoposide, Ara-C and cyclophosphamide (BEAC = 183). The remaining patients received regimens of either BCNU, etoposide, cyclophosphamide and hydrea (BECH = 40) or ifosfamide, carboplatin and etoposide (ICE = 10) or cyclophosphamide, BCNU, and etoposide (CBV = 2).
Bone marrow was harvested while patients were under general anesthesia. Marrow was collected for a minimum nucleated cell count of 2.0 ϫ 10 8 /kg and frozen at a controlled rate and preserved in 10% dimethylsulfoxide. Before April 1991, peripheral blood progenitor cells were collected without chemotherapy or cytokine mobilization. Subsequently granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF), erythropoietin, or PIXY-321 were used, depending on the mobilization trial in effect at the time. Peripheral blood progenitor cells were preserved in 5% DMSO and 6% hydroxyethyl starch and frozen at Ϫ13°C and stored in liquid nitrogen. Prior to 1992, patients who had histologically negative bone marrow received autologous bone marrow for hematopoietic rescue, while those who had never had a positive bone marrow sample or who had bone marrow that was unable to be harvested received an unmobilized peripheral stem cell graft. After 1992, patients were randomized to autologous mobilized peripheral stem cell vs autologous bone marrow transplant. Between January 1988 and April 1991, patients received hematopoietic growth factors or placebo immediately after reinfusion of autologous stem cells as part of clinical trials. After April 1991, hematopoietic growth factors were used routinely. The site of care was primarily the inpatient setting until 1992, and subsequently, outpatient care was emphasized for patients who were clinically, socially, and psychologically able to tolerate this treatment setting.
Results
The transplant team performed a total of 427 autologous SCT for NHL between 1989 and 1997, of which 353 are included in these analyses (Table 1 ). Almost 60% of the patients were male; the mean age increased steadily from 35.6 years in 1989 to 47.2 years in 1995. The percentage of patients who had bone marrow as their stem cell source ranged from 34% in 1989 to 42% in 1995.
The average length of the inpatient transplantation stay decreased steadily from 42.5 days in 1989 to 37.6 days in 1991, and to 11.9 days by 1995. As a consequence, average transplant hospitalization room costs dropped 80% during the 7 year study interval. Additional inpatient room costs (which included pretransplant and post-transplant hospitalization costs) declined until 1991 while outpatient room costs climbed during this same time period; subsequently both remained stable. When the room costs of all three time periods were evaluated collectively a 65% drop in total room costs was revealed.
Similar to total room costs, total laboratory, radiology, pharmaceutical, supportive care, and professional costs decreased steadily over time, while their individual contributions to the comprehensive total experience cost remained fairly constant every year ( Figure 1 ). Although the figure portrays only the total costs related to each cost driver (ie summed outpatient, transplant, and additional inpatient room costs), notable time-specific changes which impacted the charted costs are highlighted. Total laboratory costs fell from a high in 1990 to their lowest level in 1995, representing an overall 70% decline. The largest decreases were during the inpatient time periods, with inpatient transplant laboratory costs dropping 88% overall and additional inpatient laboratory costs dropping by 50% during the 7 year period. Total radiology costs initially increased between 1989 and 1991, but then declined steadily thereafter. At a decline of 86% between 1991 and 1995, radiographic costs associated with the transplant period were markedly reduced, while radiographic costs accumulated during the additional inpatient periods were always minimal. Although total experience pharmacy costs decreased by 72% during the study period, outpatient pharmaceutical costs increased by 10-fold, transplant costs decreased steadily by 76%, and pharmaceutical costs attributable to the additional inpatient periods remained reduced. Supportive care costs remained relatively insignificant during all three time periods. Total professional fees also decreased over time, but the magnitude and percent of the change was small. The next step in the study was to describe the comprehensive total experience cost not on the basis of the individual cost-driver contributions as described above, but by combining the six outpatient, transplant, and additional inpatient cost-driver categories (Figure 2 ). Average and median total outpatient costs climbed initially to a high in 1991, decreased slightly, and remained stagnant between 1992 and 1995. Total transplant hospitalization costs were highest in 1989, but mean and median levels dropped 81% and 87%, respectively, by 1995. Total additional inpatient costs declined initially until 1993, after which they increased only slightly. The summation of total outpatient, transplant, and additional inpatient costs revealed a largescale decline in comprehensive total experience costs. Total experience costs, which included all costs accrued at UNMC between the patient's initial consult and program dismissal following recovery, decreased by 14% between 1989 and 1991, and by an additional 51% between 1992 and 1995. Overall, average total experience costs, measured in constant dollars, declined 65% between 1989 and 1995. The contribution, to the total experience cost, of outpatient, transplant and additional inpatient periods changed dramatically, with most of the changes occurring between 1992 and 1995. Transplant hospitalization costs decreased from 83% in 1989 to 71% in 1992, and to merely 45% of the total experience cost by 1995, while outpatient costs increased from 14% in 1989 to 26% in 1992, and 49% of the total costs by 1995. Additional inpatient costs amounted to less than 5% of the total experience amount in all 7 years ( Figure 3) .
Discussion
This study demonstrates that the duration of the transplant admission decreased from a mean of 42.5 days to 37.6 in the first 3 years evaluated, and to 11.9 days by 1995, while comprehensive costs of care decreased 14% by 1991, and an additional 51% between 1991 and 1995 for NHL patients who received high-dose therapy and stem cell support at UNMC. The major determinant of lower costs was the 80% decrease in transplant hospitalization room costs. As a result of dramatic decreases in dollars spent on all inpatient transplant resources, and the relatively stagnant costs associated with outpatient and additional inpatient resources over time, outpatient costs increased relative to the decreasing transplant hospitalization costs. Total outpatient costs made a somewhat disproportionate contribution of only 14% of the total experience in 1989, 26% by 1992, but 49% by 1995.
Researchers have attributed lower health care costs over time to one of three hypotheses as follows: (1) hospitals that have treated large numbers of patients are further along on the learning curve in caring for the relevant patients by using medical resources more efficiently; (2) a referral system has been established so that as hospitals gain experience, they admit patients who are better candidates for the procedure; or (3) technologic improvements have occurred. [12] [13] [14] [15] [16] We previously reported on empirical evidence of the economic benefit of technological advances for SCT from six large referral centers in France and the United States in 1989 and 1990. 17 In that study, the use of hematopoietic colony-stimulating factors for SCT patients was associated with a 1 week shortening of hospitalization and a $10 000 decrease in overall cost. Between 1989 and 1990 the 5 day decrease in length of stay and the 15% decrease in costs found in the present study were attributable to technological advances including both the introduction of hematopoietic colony-stimulating factors and the use of unmobilized peripheral stem cells (hypothesis No. 3). In addition, between 1992 and 1995 the three-fold larger improvement in overall cost reductions appears to be related primarily to organizational changes such as the coordinated use of outpatient facilities (hypothesis No. 1) as well as improvements in technology through the use of mobilized peripheral blood stem cells (hypothesis No. 3). During this same time period, the referral system did not appear to result in better transplant candidates over time (hypothesis No. 2). Instead, less favorable candidates underwent the procedure as technology and the safety of the procedure improved, as evidenced by the 12 year increase in mean patient age between 1989 and 1995. Our study seems to suggest that the incorporation of both organization and technological improvements have favorably impacted overall transplantation costs in an additive, and possibly synergistic manner without narrowing patient inclusion.
There is previous evidence supporting the concept that both organizational improvements and technological advances can have large effects on cost improvements.
18
For women with breast cancer undergoing autologous SCT, shortening of hospitalizations by 1 week or less has been associated with the use of hematopoietic colony-stimulating factors and peripheral stem cell support. However, two-fold or larger decreases in the average length of stay and overall costs were not reported until programs developed wellcoordinated outpatient facilities. These findings mirror the results for NHL patients that we have reported in this study, suggesting that the organizational effects are larger in magnitude than the technological effects.
The limitations of our data should be considered. First, the data allow us to evaluate only those patients treated at the program with the largest experience to date in autotransplants of patients with lymphomas. Additional data analyses are needed at other medical centers to evaluate the generalizability of these results. Second, our results do not definitively identify which factors account for the changes in costs of care. Improvements in costs reflect changes in the patient case-mix, providers, and hospital characteristics. Additional studies are needed to evaluate the independent effects of differences in patient comorbidity, preparative regimens, lymphoma histology, and the use of specific supportive care technologies and outpatient facilities. On the other hand, it seems reasonable to infer from these results, that direct costs are not simply being shifted from the transplant hospitalization to peri-transplant settings as supportive care technologies continue to facilitate outpatient care.
As care is shifted from the inpatient setting to the outpatient arena indirect and opportunity costs begin to contribute more significantly to the total cost of care and should ideally be considered along with direct outpatient costs. This study fails to capture these relevant expenses which include travel, housing procurement, and lost wages for both the patient and their care giver.
Fixed costs associated with such things as heating, lighting, and other facility overheads are assessed to each patient using the daily room charge and were therefore not held constant as the case rate changed. Even though it might be argued that economies of scale should be considered, cost savings from improvements in resource utilization far outweighed the smaller savings associated with spreading fixed costs over a larger annual population of transplant patients. The largest annual caseload increase was 16 in 1993, but unchanged in 1995 indicating that economic benefits due to volume effects were small.
In conclusion, our results have important policy implications with respect to the debate over regionalization of care for SCT patients. Improvements in medicine that reflect technological advances can be efficiently disseminated through educational programs, scientific meeting presentations, and journal publications. To the extent that SCT improvements are related to these technological advances, there would be little rationale to support regionalization of services. Conversely, effects that are associated with organizational changes (such as coordinated outpatient centers) require large amounts of capital expenditures for procurement of facilities and experienced personnel to use these resources and novel technologies efficiently. Geographic areas with large numbers of transplant centers are unlikely to fully realize these organizational benefits at each of the centers; regionalization of services is likely to be a more efficient policy. Our findings from UNMC, which serves as a regionalized center of excellence, provide empirical evidence that this large transplant center has been able to decrease costs of care through opportune use of organizational changes, as well as, through a lesser extent, efficient adoption of technological advances. The striking decreases in costs since 1991 reported in our study suggest that policy makers would be wise to limit the diffusion of transplant programs to large centers of excellence which are able to both develop comprehensive outpatient programs as well as rapidly adopt new technological advances.
